IS7402A - New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX - Google Patents
New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IXInfo
- Publication number
- IS7402A IS7402A IS7402A IS7402A IS7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A
- Authority
- IS
- Iceland
- Prior art keywords
- producing
- calcium
- methods
- new
- forms
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 2
- 229960005370 atorvastatin Drugs 0.000 title 2
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/005384 WO2003070702A1 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7402A true IS7402A (en) | 2004-08-13 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7402A IS7402A (en) | 2002-02-15 | 2004-08-13 | New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (en) |
| JP (2) | JP2005519076A (en) |
| KR (1) | KR100724515B1 (en) |
| CN (1) | CN100406436C (en) |
| AU (1) | AU2003217653A1 (en) |
| CA (1) | CA2475864A1 (en) |
| DE (1) | DE03713610T1 (en) |
| ES (1) | ES2241507T1 (en) |
| HR (1) | HRP20040768A2 (en) |
| IS (1) | IS7402A (en) |
| MX (1) | MXPA04007939A (en) |
| NO (1) | NO20043842L (en) |
| PL (1) | PL372303A1 (en) |
| WO (1) | WO2003070702A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| HRP20040767A2 (en) | 2002-02-19 | 2004-12-31 | Teva Pharma | Desolvating solvates of atorvastatin hemi-calcium |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| JP2008506764A (en) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | [R- (R *, R *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- Novel form of 1H-pyrrole-1-heptanoic acid calcium salt (2: 1) |
| WO2006012499A2 (en) * | 2004-07-22 | 2006-02-02 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| SK288276B6 (en) * | 2005-04-08 | 2015-06-02 | Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság | Process for preparation of crystalline atorvastatin hemicalcium salt polymorph form |
| ATE466840T1 (en) | 2005-11-21 | 2010-05-15 | Warner Lambert Co | NEW FORMS OF ÄR-(R*,R*)Ü-2-(4-FLUORPHENYL)-B,D-DIHYDROXY-5-(-METHYLETHYL)-3-PHENYL-4-Ä(PHENYLAMINO)CARBONYLÜ-1H-PYRROLE -1-HEPTANIC ACID MAGNESIUM |
| US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| JP2010520273A (en) * | 2007-03-02 | 2010-06-10 | ドン・ア・ファーム・カンパニー・リミテッド | A novel crystalline form of pyrrolylheptanoic acid derivatives |
| KR20120011249A (en) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | Novel crystalline forms of atorvastatin hemicalcium salts, hydrates thereof, and methods for preparing the same |
| KR101324862B1 (en) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof |
| MY180626A (en) | 2013-11-15 | 2020-12-03 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN105055357A (en) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | Atorvastatin calcium composition tablet for treating hypercholesteremia |
| KR101723783B1 (en) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20002029B (en) * | 1995-07-17 | 2000-04-10 | Warner Lambert Company Us | (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin) |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| ES2234699T3 (en) * | 1999-11-17 | 2005-07-01 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of ATORVASTATIN CALCIUM. |
| ES2258030T3 (en) * | 1999-12-17 | 2006-08-16 | Pfizer Science And Technology Ireland Limited | PROCEDURE TO PRODUCE ATORVASTATIN CALCIUM CRYSTALINE. |
| EP1584616A1 (en) * | 1999-12-17 | 2005-10-12 | Pfizer Science and Technology Ireland Limited | Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt |
| KR100704213B1 (en) * | 2000-11-03 | 2007-04-10 | 테바 파마슈티컬 인더스트리즈 리미티드 | Atorvastatin Hemi-Calcium GI Type |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622477A1 (en) * | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| BR0210666A (en) * | 2001-06-29 | 2004-10-05 | Warner Lambert Co | Crystalline forms of the [r- (r *, r *)] -2- (4-fluorophenyl) beta, delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [( phenylamino) carbonyl] -1h-pyrrol-1-heptanoic (2: 1) (atorvastatin) |
| AU2002255479B2 (en) * | 2001-07-30 | 2008-09-11 | Dr. Reddy's Laboratories Ltd. | Crystalline forms VI and VII of atorvastatin clacium |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 PL PL03372303A patent/PL372303A1/en not_active Application Discontinuation
- 2003-02-19 DE DE03713610T patent/DE03713610T1/en active Pending
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/en not_active Expired - Fee Related
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 CN CNB038082071A patent/CN100406436C/en not_active Expired - Fee Related
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en not_active Ceased
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/en not_active Withdrawn
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 HR HR20040768A patent/HRP20040768A2/en not_active Application Discontinuation
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/en unknown
- 2003-02-19 ES ES03713610T patent/ES2241507T1/en active Pending
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/en unknown
- 2004-09-14 NO NO20043842A patent/NO20043842L/en not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL372303A1 (en) | 2005-07-11 |
| CN1646490A (en) | 2005-07-27 |
| MXPA04007939A (en) | 2004-11-26 |
| NO20043842L (en) | 2004-09-14 |
| AU2003217653A1 (en) | 2003-09-09 |
| EP1480950A1 (en) | 2004-12-01 |
| ES2241507T1 (en) | 2005-11-01 |
| KR100724515B1 (en) | 2007-06-04 |
| EP1480950A4 (en) | 2005-05-18 |
| JP2005519076A (en) | 2005-06-30 |
| DE03713610T1 (en) | 2005-10-20 |
| HRP20040768A2 (en) | 2005-06-30 |
| CN100406436C (en) | 2008-07-30 |
| WO2003070702A1 (en) | 2003-08-28 |
| KR20040081202A (en) | 2004-09-20 |
| CA2475864A1 (en) | 2003-08-28 |
| JP2009235083A (en) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7402A (en) | New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX | |
| PT1398327E (en) | METHOD OF PRODUCTION OF HYDROXYALQUIL-AMIDO DERIVATIVES | |
| CY2015015I1 (en) | PRODUCTION OF THIACOMYCIN | |
| IS7261A (en) | N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and methods for producing them | |
| DK1654438T3 (en) | Process for natural gas production | |
| IS2939B (en) | Pyrosolo-quinazoline derivatives, their method of production and their use as kinase inhibitors | |
| IS7467A (en) | Lansoprazole multiple synthesis and methods of producing them | |
| DK1518827T3 (en) | Crystallized IM-12 solid and process for its preparation | |
| IS8035A (en) | New photostable stable groups for improved methods of producing oligomeric arrays | |
| EP1626718A4 (en) | Methods of treating ischemic related conditions | |
| IS8447A (en) | A method of producing gamma-carboxylated protein | |
| AU2003261191A8 (en) | Methods for producing biopolymers | |
| HRP20150163T1 (en) | PROCEDURE FOR THE PRODUCTION OF N-SUBSTITUTED 2-CYANOPYROLIDINE | |
| PL394821A1 (en) | Production method of combrestinates | |
| IS8416A (en) | Method of production of CCR-2 antagonist | |
| IS7069A (en) | Method of producing zaleplon | |
| DK1890570T3 (en) | Toothbrush head and method of manufacture thereof | |
| IS7981A (en) | Method for producing microsystems | |
| SE0301664L (en) | Method for compression of data | |
| FI20031467L (en) | Method and arrangement for producing experiences | |
| EP1600511A4 (en) | Method of treating ischemic disease | |
| NO20043568D0 (en) | Method of Preparing Citalopram | |
| FI20031639A7 (en) | Method for producing somatic embryos of conifers | |
| FI20010892L (en) | Method for producing xylitol | |
| ITMI20021432A0 (en) | METHOD FOR PRODUCING CEPHALOSPORINS |